Patiromer
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Patiromer
- 2 propenoic acid 2 fluoro polymer with diethenylbenzene and 1 7 octadiene
- 2-PROPENOIC ACID, 2-FLUORO-, POLYMER WITH DIETHENYLBENZENE AND 1,7-OCTADIENE
- cross linked polymer of 2 fluoroprop 2 enoate with diethenylbenzene and octa 1 7 diene
- CROSS-LINKED POLYMER OF 2-FLUOROPROP-2-ENOATE WITH DIETHENYLBENZENE AND OCTA-1,7-DIENE
- patiromer
- Patiromer
- PATIROMER [USAN]
- Patiromer [WHO-DD]
- Patiromer 25.2 g
- Patiromer Powder for Oral Suspension (Part A)
- patiromer usan
- patiromer who dd
- ATC classification codes
- V03AE09
- CAS registry numbers
- 1260643-52-4
- ChEMBL ID
- CHEMBL2107875
- RxNorm IDs (RxCUI)
- 1716203
- FDA ingredient codes (UNII)
- 1FQ2RY5YHH
- Status
- Authorised
- Status date
- 19 Jul 2017
- Authorisation date
- 19 Jul 2017
- Approved indications
- Veltassa is indicated for the treatment of hyperkalaemia in adults and adolescents aged 12 to 17 years.
- Product number
- EMEA/H/C/004180
- Authorisation holder
- Vifor Fresenius Medical Care Renal Pharma France
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Hyperkalemia
European medicines record
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -mer; -tirom-
Mechanisms of action
- Mechanism
- Potassium chelating agent
- Action type
- CHELATING_AGENT
- Target
- Potassium
- Condition
- Heart Failure
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003144
- Subject identifier
- D006333
- Condition
- Renal Insufficiency, Chronic
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003884
- Subject identifier
- D051436
- Condition
- Hyperkalemia
- Highest recorded phase
- 3
- Condition identifier
- HP:0002153
- Subject identifier
- D006947
- Condition identifier
- EFO_0003144
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003884
- Highest recorded phase
- 3
- Condition identifier
- HP_0002153
- Highest recorded phase
- 3
- Condition identifier
- HP_0002153
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005016
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005044
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005252
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005300
- Highest recorded phase
- 2
- Event
- abdominal discomfort
- Reports
- 101
- Reporting signal score
- 107.203
- Event
- abdominal pain upper
- Reports
- 72
- Reporting signal score
- 39.7723
- Event
- blood calcium increased
- Reports
- 19
- Reporting signal score
- 36.9794
- Event
- blood potassium abnormal
- Reports
- 15
- Reporting signal score
- 44.1056
- Event
- blood potassium decreased
- Reports
- 38
- Reporting signal score
- 51.0784
- Event
- blood potassium increased
- Reports
- 168
- Reporting signal score
- 565.857
- Event
- bowel movement irregularity
- Reports
- 12
- Reporting signal score
- 24.3789
- Event
- constipation
- Reports
- 388
- Reporting signal score
- 740.262
- Event
- dialysis
- Reports
- 83
- Reporting signal score
- 231.023
- Event
- diarrhoea
- Reports
- 267
- Reporting signal score
- 141.277
- Event
- faecaloma
- Reports
- 14
- Reporting signal score
- 26.0113
- Event
- faeces hard
- Reports
- 15
- Reporting signal score
- 46.0811
- Event
- flatulence
- Reports
- 74
- Reporting signal score
- 142.377
- Event
- headache
- Reports
- 21
- Reporting signal score
- 25.1651
- Event
- hospice care
- Reports
- 21
- Reporting signal score
- 45.3791
- Event
- hospitalisation
- Reports
- 335
- Reporting signal score
- 684.922
- Event
- hypercalcaemia
- Reports
- 20
- Reporting signal score
- 24.2863
- Event
- hyperkalaemia
- Reports
- 36
- Reporting signal score
- 30.4468
- Event
- muscle spasms
- Reports
- 58
- Reporting signal score
- 24.5666
- Event
- product colour issue
- Reports
- 45
- Reporting signal score
- 175.203
- Event
- product dose omission issue
- Reports
- 34
- Reporting signal score
- 21.761
- Event
- pyrexia
- Reports
- 11
- Reporting signal score
- 24.318
- Event
- renal transplant
- Reports
- 12
- Reporting signal score
- 29.4215
- NCT01130597
- NCT02033317
- NCT03087058
- NCT03799926
- NCT03888066
- NCT04955678
- NCT05766839
- NCT03740048
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
- 53436-010
- 53436-084
- 53436-168
- 53436-252
Related records
Trials (86)
- [11C]Carfentanil PET Study of GSK1521498
- A Clinical Trial of PRAX-944 in Participants With Essential Tremor
- A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021
- A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
- A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
- A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects
- A Pilot Trial of Twice-weekly Versus Thrice-weekly Hemodialysis in Patients With Incident End-stage Kidney Disease
- A Study Assessing HMB-002 in Participants With Von Willebrand Disease
- A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)
- A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons
- A Study of AB-218 in Patients With IDH1 Mutated Low Grade Glioma
- A Study of AZD8233 in Participants With Dyslipidemia.
- A Study of LY3143753 and LY3185643 in Healthy Participants
- A Study of NP-201 Acetate Injection in Healthy Adult Volunteers and in Patients With Mild-To-Moderate Active Ulcerative Colitis
- A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
- A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0914
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
- A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GLWL-01
In development for (2)
- Chronic kidney disease Phase 3
- Heart failure Phase 2